

Stephen W Fesik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/458228/publications.pdf>

Version: 2024-02-01

67
papers

14,705
citations

108046

37
h-index

120465

65
g-index

69
all docs

69
docs citations

69
times ranked

19611
citing authors

#	ARTICLE	IF	CITATIONS
1	WIN site inhibition disrupts a subset of WDR5 function. <i>Scientific Reports</i> , 2022, 12, 1848.	1.6	10
2	Synergistic action of WDR5 and HDM2 inhibitors in SMARCB1-deficient cancer cells. <i>NAR Cancer</i> , 2022, 4, zcac007.	1.6	8
3	Discovery of Potent Orally Bioavailable WD Repeat Domain 5 (WDR5) Inhibitors Using a Pharmacophore-Based Optimization. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 6287-6312.	2.9	15
4	Fragment-Based Discovery of Small Molecules Bound to T-Cell Immunoglobulin and Mucin Domain-Containing Molecule 3 (TIM-3). <i>Journal of Medicinal Chemistry</i> , 2021, 64, 14757-14772.	2.9	13
5	Impact of WIN site inhibitor on the WDR5 interactome. <i>Cell Reports</i> , 2021, 34, 108636.	2.9	29
6	Discovery and Structure-Based Optimization of Potent and Selective WD Repeat Domain 5 (WDR5) Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 656-675.	2.9	33
7	Discovery of Sulfonamide-Derived Agonists of SOS1-Mediated Nucleotide Exchange on RAS Using Fragment-Based Methods. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 8325-8337.	2.9	20
8	Discovery of WD Repeat-Containing Protein 5 (WDR5)â€MYC Inhibitors Using Fragment-Based Methods and Structure-Based Design. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 4315-4333.	2.9	47
9	Reply to Tran et al.: Dimeric KRAS proteinâ€protein interaction stabilizers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 3365-3367.	3.3	13
10	Structural Elucidation of Peptide Binding to KLHL-12, a Substrate Specific Adapter Protein in a Cul3-Ring E3 Ligase Complex. <i>Biochemistry</i> , 2020, 59, 964-969.	1.2	17
11	Targeting MYC through WDR5. <i>Molecular and Cellular Oncology</i> , 2020, 7, 1709388.	0.3	24
12	WDR5 is a conserved regulator of protein synthesis gene expression. <i>Nucleic Acids Research</i> , 2020, 48, 2924-2941.	6.5	40
13	Drugging an undruggable pocket on KRAS. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 15823-15829.	3.3	280
14	Targeting WDR5: A WINning Anti-Cancer Strategy?. <i>Epigenetics Insights</i> , 2019, 12, 251686571986528.	0.6	25
15	Fragment-based screening of programmed death ligand 1 (PD-L1). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 786-790.	1.0	48
16	Displacement of WDR5 from Chromatin by a WIN Site Inhibitor with Picomolar Affinity. <i>Cell Reports</i> , 2019, 26, 2916-2928.e13.	2.9	70
17	Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 3971-3988.	2.9	44
18	Small Molecule SOS1 Agonists Modulate MAPK and PI3K Signaling <i>via</i> Independent Cellular Responses. <i>ACS Chemical Biology</i> , 2019, 14, 325-331.	1.6	15

#	ARTICLE	IF	CITATIONS
19	Interaction of the oncoprotein transcription factor MYC with its chromatin cofactor WDR5 is essential for tumor maintenance. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 25260-25268.	3.3	69
20	Discovery and Optimization of Salicylic Acid-Derived Sulfonamide Inhibitors of the WD Repeat-Containing Protein 5â€“MYC Proteinâ€“Protein Interaction. Journal of Medicinal Chemistry, 2019, 62, 11232-11259.	2.9	40
21	High-throughput screening identifies small molecules that bind to the RAS:SOS:RAS complex and perturb RAS signaling. Analytical Biochemistry, 2018, 548, 44-52.	1.1	48
22	Small Moleculeâ€“Mediated Activation of RAS Elicits Biphasic Modulation of Phospho-ERK Levels that Are Regulated through Negative Feedback on SOS1. Molecular Cancer Therapeutics, 2018, 17, 1051-1060.	1.9	34
23	Optimization of Potent and Selective Tricyclic Indole Diazepinone Myeloid Cell Leukemia-1 Inhibitors Using Structure-Based Design. Journal of Medicinal Chemistry, 2018, 61, 2410-2421.	2.9	47
24	A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia. Cancer Discovery, 2018, 8, 1566-1581.	7.7	250
25	Discovery and Structure-Based Optimization of Benzimidazole-Derived Activators of SOS1-Mediated Nucleotide Exchange on RAS. Journal of Medicinal Chemistry, 2018, 61, 8875-8894.	2.9	41
26	Discovery of Aminopiperidine Indoles That Activate the Guanine Nucleotide Exchange Factor SOS1 and Modulate RAS Signaling. Journal of Medicinal Chemistry, 2018, 61, 6002-6017.	2.9	33
27	Understanding the Species Selectivity of Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors. Biochemistry, 2018, 57, 4952-4958.	1.2	6
28	Discovery of Quinazolines That Activate SOS1-Mediated Nucleotide Exchange on RAS. ACS Medicinal Chemistry Letters, 2018, 9, 941-946.	1.3	24
29	Discovery of Potent 2-Aryl-6,7-dihydro-5<i>H</i>-pyrrolo[1,2- <i>a< 2018,="" 5623-5642.<="" 61,="" and="" as="" chemistry,="" design.="" fragment-based="" i>]imidazoles="" inhibitors="" journal="" medicinal="" methods="" of="" structure-based="" td="" using="" wdr5-win-site=""> <td>2.9</td> <td>54</td> </i>a<>	2.9	54
30	BAX-BAK heterodimer as a pharmacodynamic biomarker of on-target drug action of Mcl-1 inhibitors to evaluate in-vivo effectiveness.. Journal of Clinical Oncology, 2018, 36, 2582-2582.	0.8	1
31	Structure of a Myeloid cell leukemia-1 (Mcl-1) inhibitor bound to drug site 3 of Human Serum Albumin. Bioorganic and Medicinal Chemistry, 2017, 25, 3087-3092.	1.4	16
32	MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation. Cell Metabolism, 2017, 26, 633-647.e7.	7.2	449
33	Recent advancements in the discovery of proteinâ€“protein interaction inhibitors of replication protein A. MedChemComm, 2017, 8, 259-267.	3.5	5
34	Discovery and biological characterization of potent myeloid cell leukemiaâ€“1 inhibitors. FEBS Letters, 2017, 591, 240-251.	1.3	49
35	Identification and Optimization of Anthranilic Acid Based Inhibitors of Replication Proteinâ€“A. ChemMedChem, 2016, 11, 893-899.	1.6	13
36	Twenty years on: the impact of fragments on drug discovery. Nature Reviews Drug Discovery, 2016, 15, 605-619.	21.5	711

#	ARTICLE	IF	CITATIONS
37	Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 2054-2066.	2.9	114
38	Interaction with WDR5 Promotes Target Gene Recognition and Tumorigenesis by MYC. <i>Molecular Cell</i> , 2015, 58, 440-452.	4.5	224
39	Discovery of Tricyclic Indoles That Potently Inhibit Mcl-1 Using Fragment-Based Methods and Structure-Based Design. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 3794-3805.	2.9	84
40	Diphenylpyrazoles as Replication Protein A Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 140-145.	1.3	18
41	Small molecule Mcl-1 inhibitors for the treatment of cancer. , 2015, 145, 76-84.		145
42	Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 3401-3406.	3.3	165
43	Fragment-Based Screening of the Bromodomain of ATAD2. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 9687-9692.	2.9	75
44	Drugging the undruggable RAS: Mission Possible?. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 828-851.	21.5	1,484
45	A method for the second-site screening of K-Ras in the presence of a covalently attached first-site ligand. <i>Journal of Biomolecular NMR</i> , 2014, 60, 11-14.	1.6	32
46	Discovery of a Potent Stapled Helix Peptide That Binds to the 70N Domain of Replication Protein A. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 2455-2461.	2.9	49
47	Abstract IA13: Discovery of K-Ras inhibitors for the treatment of cancer. , 2014, , .		0
48	Abstract IA17: Discovery of K-Ras inhibitors for the treatment of cancer. , 2014, , .		0
49	Surface Reengineering of RPA70N Enables Cocrystallization with an Inhibitor of the Replication Protein A Interaction Motif of ATR Interacting Protein. <i>Biochemistry</i> , 2013, 52, 6515-6524.	1.2	19
50	Discovery of a Potent Inhibitor of Replication Protein A Protein-Protein Interactions Using a Fragment-Linking Approach. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 9242-9250.	2.9	59
51	Discovery of Potent Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods and Structure-Based Design. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 15-30.	2.9	248
52	Discovery of Protein-Protein Interaction Inhibitors of Replication Protein A. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 601-605.	1.3	27
53	Fragment-based drug discovery using NMR spectroscopy. <i>Journal of Biomolecular NMR</i> , 2013, 56, 65-75.	1.6	179
54	Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-Mediated Activation. <i>Angewandte Chemie - International Edition</i> , 2012, 51, 6140-6143.	7.2	419

#	ARTICLE	IF	CITATIONS
55	A high-throughput fluorescence polarization anisotropy assay for the 70N domain of replication protein A. <i>Analytical Biochemistry</i> , 2012, 421, 742-749.	1.1	39
56	ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor. <i>Cancer Research</i> , 2008, 68, 3421-3428.	0.4	1,666
57	Influence of Bcl-2 Family Members on the Cellular Response of Small-Cell Lung Cancer Cell Lines to ABT-737. <i>Cancer Research</i> , 2007, 67, 1176-1183.	0.4	283
58	Discovery and Structure-Activity Relationship of Antagonists of B-Cell Lymphoma 2 Family Proteins with Chemopotential Activity in Vitro and in Vivo. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 1165-1181.	2.9	126
59	An inhibitor of Bcl-2 family proteins induces regression of solid tumours. <i>Nature</i> , 2005, 435, 677-681.	13.7	3,157
60	Druggability Indices for Protein Targets Derived from NMR-Based Screening Data. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 2518-2525.	2.9	497
61	Structural biology of the Bcl-2 family of proteins. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2004, 1644, 83-94.	1.9	602
62	NMR-Based Screening of Proteins Containing ¹³ C-Labeled Methyl Groups. <i>Journal of the American Chemical Society</i> , 2000, 122, 7898-7904.	6.6	207
63	Design of Adenosine Kinase Inhibitors from the NMR-Based Screening of Fragments. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 4781-4786.	2.9	81
64	Privileged Molecules for Protein Binding Identified from NMR-Based Screening. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 3443-3447.	2.9	360
65	DRUG DESIGN: Discovering High-Affinity Ligands for Proteins. <i>Science</i> , 1997, 278, 497-499.	6.0	201
66	Three-dimensional structures of proteins involved in programmed cell death. <i>Journal of Molecular Biology</i> , 1997, 274, 291-302.	2.0	63
67	Structure of Bcl-xL-Bak Peptide Complex: Recognition Between Regulators of Apoptosis. <i>Science</i> , 1997, 275, 983-986.	6.0	1,394